| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10909263 | Leukemia Research | 2012 | 7 Pages |
Abstract
Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lenka Sedlarikova, Lenka Kubiczkova, Sabina Sevcikova, Roman Hajek,